HeartBeam Inc. (NASDAQ: BEAT) announced the launch of a pilot study focused on evaluating its proprietary on-demand 12-lead ECG patch for detecting coronary artery disease and ischemia. The study marks a significant step in the development of the HeartBeam patch, which has the potential to disrupt the $2 billion long-term continuous monitor and mobile cardiac telemetry markets.
Coronary artery disease remains one of the most urgent and widespread health threats worldwide, contributing to millions of deaths each year and often progressing silently until a major cardiac event occurs. As healthcare providers search for faster and more accessible ways to identify high-risk patients earlier, HeartBeam has launched this new pilot study designed to evaluate its technology.
“Ischemia detection has not been possible on patch-based ambulatory monitors, and they do not provide clinical-grade insights over an extended period of time,” said HeartBeam CEO Robert Eno. “The HeartBeam patch is designed to change that. A device capable of generating an on-demand 12-lead ECG for ischemia detection could significantly improve patient outcomes.”
The study represents a critical evaluation of the patch’s ability to detect inadequate blood flow and oxygen supply to tissue, a condition that often precedes heart attacks. The patch is designed to be worn by patients over an extended period, allowing for continuous monitoring and on-demand ECG recordings when symptoms occur. This capability could enable earlier detection of cardiac issues and reduce the need for more invasive diagnostic procedures.
The potential impact of this technology is substantial. Current patch-based monitors primarily track heart rhythm and do not provide the detailed electrical activity captured by a 12-lead ECG, which is the gold standard for diagnosing ischemia. If successful, the HeartBeam patch could offer a non-invasive, long-term monitoring solution that provides clinical-grade data comparable to in-hospital ECG tests.
HeartBeam’s announcement comes at a time when cardiovascular disease continues to intensify as populations age and risk factors become more common. The company’s focus on developing a patch that can generate on-demand 12-lead ECGs addresses a significant gap in ambulatory monitoring technology.
For more information about HeartBeam and its latest developments, visit the company’s newsroom at https://nnw.fm/BEAT.
NetworkNewsWire is a specialized communications platform with a focus on financial news and content distribution. For more information, visit https://www.NetworkNewsWire.com.
